GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.
Joining a minimalistic wave in pharma marketing, Novo said the change increases memorability and relevance.
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm.
Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.
The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy.
Share prices dropped last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.
